These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35932588)

  • 41. Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?
    Alexandrescu S; Korshunov A; Lai SH; Dabiri S; Patil S; Li R; Shih CS; Bonnin JM; Baker JA; Du E; Scharnhorst DW; Samuel D; Ellison DW; Perry A
    Brain Pathol; 2016 Mar; 26(2):215-23. PubMed ID: 26238627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
    Purkait S; Bansal S; Malgulwar PB
    Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma.
    Nakamura T; Fukuoka K; Nakano Y; Yamasaki K; Matsushita Y; Yamashita S; Ikeda J; Udaka N; Tanoshima R; Shiba N; Tateishi K; Yamanaka S; Yamamoto T; Hirato J; Ichimura K
    Cancer Sci; 2019 Feb; 110(2):828-832. PubMed ID: 30609203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?
    Mahajan S; Singh J; Dandapath I; Jha P; Chaturvedi S; Ahuja A; Bhardwaj M; Saran R; Garg A; Sharma MC; Manjunath N; Suri A; Sarkar C; Suri V
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):84-95. PubMed ID: 38158760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
    Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
    Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma.
    Lucas CG; Davidson CJ; Alashari M; Putnam AR; Whipple NS; Bruggers CS; Mendez JS; Cheshier SH; Walker JB; Ramani B; Cadwell CR; Sullivan DV; Lu R; Mirchia K; Van Ziffle J; Devine P; Goldschmidt E; Hervey-Jumper SL; Gupta N; Oberheim Bush NA; Raleigh DR; Bollen A; Tihan T; Pekmezci M; Solomon DA; Phillips JJ; Perry A
    J Neuropathol Exp Neurol; 2022 Jul; 81(8):650-657. PubMed ID: 35703914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA).
    Hofer S; Berthod G; Riklin C; Rushing E; Feilchenfeldt J
    Acta Oncol; 2016; 55(1):122-3. PubMed ID: 25811650
    [No Abstract]   [Full Text] [Related]  

  • 49. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma.
    Marucci G; Morandi L
    J Neurooncol; 2011 Nov; 105(2):397-400. PubMed ID: 21626073
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
    Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
    World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.
    Damayanti NP; Saadatzadeh MR; Dobrota E; Ordaz JD; Bailey BJ; Pandya PH; Bijangi-Vishehsaraei K; Shannon HE; Alfonso A; Coy K; Trowbridge M; Sinn AL; Zhang ZY; Gallagher RI; Wulfkuhle J; Petricoin E; Richardson AM; Marshall MS; Lion A; Ferguson MJ; Balsara KE; Pollok KE
    Sci Rep; 2023 Jun; 13(1):9163. PubMed ID: 37280243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acquired ATRX Loss and ALT Phenotype Through Tumor Recurrences in a Case of Pleomorphic Xanthoastrocytoma Suggest Their Possible Roles in Tumor Progression.
    Dal Col P; Poncet D; Rivoirard R; Vassal F; Bernichon E; Boutet C; Péoc'h M; Forest F
    J Neuropathol Exp Neurol; 2020 Sep; 79(9):1011-1014. PubMed ID: 32770176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
    Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
    [No Abstract]   [Full Text] [Related]  

  • 56. Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report.
    Yamada SM; Murakami H; Tomita Y; Nakane M; Shibui S; Takahashi M; Kawamoto M
    Diagn Pathol; 2016 Jul; 11(1):65. PubMed ID: 27449352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
    Funata N; Nobusawa S; Yamada R; Shinoura N
    Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma.
    Forest F; Dal Col P; Laville D; Court A; Rillardon M; Ramirez C; Rivoirard R; Stephan JL; Vassal F; Péoc'h M
    Exp Mol Pathol; 2021 Aug; 121():104652. PubMed ID: 34022185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].
    Belyaev AY; Shugai SV; Kobyakov GL; Strunina YV; Batalov AI; Pronin IN; Usachev DY
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(2):45-54. PubMed ID: 35412712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
    Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.